Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy

Epilepsy Research

Volumn 92, Issue 2-3, 2010, Pages 170-176

  Sergott, Robert C ^a   Bittman, Richard M ^b   Christen, Erin M ^c   Sagar, Stephen M ^d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Bittman Biostat Inc   (United States)

^c AYW Consulting   (United States)

^d LUNDBECK RESEARCH USA   (United States)

Author keywords

Clinical trial; Epilepsy; Retinopathy; Vigabatrin; Visual field constriction

Indexed keywords

VIGABATRIN;

ADULT; ARTICLE; CHILD; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; FOCAL EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PERIMETRY; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK BENEFIT ANALYSIS; SCHOOL CHILD; TREATMENT DURATION; VISION TEST; VISUAL FIELD DEFECT;

ANTICONVULSANTS; CHILD; EPILEPSIES, PARTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL COOPERATION; MALE; QUESTIONNAIRES; VIGABATRIN; VISION DISORDERS; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 78650177511     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2010.09.004     Document Type: Article

References (31)

1. Aicardi J., Mumford J.P., Dumas C., Wood S. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups. Epilepsia 1996, 37:638-642.
2. Appleton R.E., Peters A.C., Mumford J.P., Shaw D.E. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999, 40:1627-1633.
3. Baulac M., Nordmann J.P., Lanoe Y. Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic agents. Lancet 1998, 352:546.
4. Ben-Menachem E. Vigabatrin. Epilepsia 1995, 36(Suppl. 2):S95-S104.
5. Besch D., Kurtenbach A., Apfelstedt-Sylla E., Sadowski B., Dennig D., Asenbauer C., et al. Visual field constriction and electrophysiological changes associated with vigabatrin. Doc. Ophthalmol. 2002, 104:151-170.
6. Bruni J., Guberman A., Vachon L., Desforges C. Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure 2000, 9:224-232.
7. Chiron C., Dulac O., Luna D., Palacios L., Mondragon S., Beaumont D., et al. Vigabatrin in infantile spasms. Lancet 1990, 335:363-364.
8. Chiron C., Dumas C., Jambaque I., Mumford J., Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. 1997, 26:389-395.
9. Durbin S., Mirabella G., Buncic J.R., Westall C.A. Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy. Invest. Ophthalmol. Vis. Sci. 2009, 50:4011-4016.
10. Eke T., Talbot J.F., Lawden M.C. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997, 314:180-181.
11. Elterman R.D., Shields W.D., Mansfield K.A., Nakagawa J. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001, 57:1416-1421.
12. French J.A., Mosier M., Walker S., Sommerville K., Sussman N. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort. Neurology 1996, 46:54-61.
13. Guberman A., Bruni J. Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group. Seizure 2000, 9:112-118.
14. Harding G.F. Severe persistent visual field constriction associated with vigabatrin. Benefit: risk ratio must be calculated for individual patients. BMJ 1998, 316:232-233.
15. Hardus P., Verduin W.M., Postma G., Stilma J.S., Berendschot T.T., Van Veelen C.W. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia 2000, 41:581-587.
16. Johnson M.A., Krauss G.L., Miller N.R., Medura M., Paul S.R. Visual function loss from vigabatrin: effect of stopping the drug. Neurology 2000, 55:40-45.
17. Kalviainen R., Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 2001, 15:217-230.
18. Kalviainen R., Nousiainen I., Mantyjarvi M., Nikoskelainen E., Partanen J., Partanen K., et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999, 53:922-926.
19. Lawden M.C., Eke T., Degg C., Harding G.F., Wild J.M. Visual field defects associated with vigabatrin therapy. J. Neurol. Neurosurg. Psychiatry 1999, 67:716-722.
20. Malmgren K., Ben-Menachem E., Frisen L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 2001, 42:609-615.
21. Newman W.D., Tocher K., Acheson J.F. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye 2002, 16:567-571.
22. Nicolson A., Leach J.P., Chadwick D.W., Smith D.F. The legacy of vigabatrin in a regional epilepsy clinic. J. Neurol. Neurosurg. Psychiatry 2002, 73:327-329.
23. Sander J.W., Trevisol-Bittencourt P.C., Hart Y.M., Shorvon S.D. Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy. J. Neurol. Neurosurg. Psychiatry 1990, 53:1008-1010.
24. Schmitz B., Schmidt T., Jokiel B., Pfeiffer S., Tiel-Wilck K., Ruther K. Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study. J. Neurol. 2002, 249:469-475.
25. Sergott R.C., Wheless J.W., Smith M.C., Westall C.A., Kardon R.H., Arnold A., et al. Evidence-based review of recommendations for visual function testing in patients treated with vigabatrin. Neuro-ophthalmology 2010, 34:20-35.
26. Stefan H.J., Bernati K., Knorr H.L.J. Visual field constriction and anti-epileptic drug treatment. Neurol. Psychiat. Brain Res. 2000, 7:185-190.
27. Vanhatalo S., Nousiainen I., Eriksson K., Rantala H., Vainionpaa L., Mustonen K., et al. Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia 2002, 43:748-756.
28. Wild J.M., Chiron C., Ahn H., Baulac M., Bursztyn J., Gandolfo E., et al. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study. CNS Drugs 2009, 23:965-982.
29. Wild J.M., Martinez C., Reinshagen G., Harding G.F. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999, 40:1784-1794.
30. Wilson E.A., Brodie M.J. Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions. BMJ 1997, 314:1693.
31. Wohlrab G., Boltshauser E., Schmitt B. Vigabatrin as a first-line drug in West syndrome: clinical and electroencephalographic outcome. Neuropediatrics 1998, 29:133-136.